Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

1.211 +0.021 (+1.76%)
Streaming Delayed Price Updated: 12:36 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 53,118
Open 1.230
Bid (Size) 1.200 (20)
Ask (Size) 1.220 (6)
Prev. Close 1.190
Today's Range 1.200 - 1.250
52wk Range 1.150 - 666.00
Shares Outstanding 198,742,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-99.63%
-99.63%
1 Month
-25.71%
-25.71%
3 Month
-75.91%
-75.91%
6 Month
-93.69%
-93.69%
1 Year
-99.60%
-99.60%

More News

Read More
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From The Law Offices of Frank R. Cruz
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Allarity Therapeutics to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.